Major trial launches to find better treatments for Flesh-Eating parasite
NCT ID NCT07463040
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial in Ethiopia will compare four different drug regimens against the standard treatment for cutaneous leishmaniasis, a parasitic skin disease. 900 patients aged 4 to 65 will be hospitalized and treated for up to 28 days, with follow-up for 6 months. The goal is to see which treatment cures all skin lesions by day 90.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sodium Stibogluconate, Miltefosine, Paromomycin, Liposomal Amphotericin B, Pentamidine isethionate
- What this could lead to
- If successful, this trial could identify a more effective treatment for cutaneous leishmaniasis, reducing the burden of this disfiguring disease in Ethiopia.
- What could go wrong
- This is a large Phase 3 trial, but results may not apply to other regions or parasite strains. Some treatments have side effects like kidney or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS LEIHMANIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ALERT Hospital
Addis Ababa, Ethiopia
-
Arba Minch General Hospital
Arba Minch, Ethiopia
-
Boru Meda General Hospital
Boru, Ethiopia